GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (OTCPK:CLRPF) » Definitions » EV-to-FCF

Clarity Pharmaceuticals (Clarity Pharmaceuticals) EV-to-FCF : -30.78 (As of May. 11, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Clarity Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Clarity Pharmaceuticals's Enterprise Value is $786.13 Mil. Clarity Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-25.54 Mil. Therefore, Clarity Pharmaceuticals's EV-to-FCF for today is -30.78.

The historical rank and industry rank for Clarity Pharmaceuticals's EV-to-FCF or its related term are showing as below:

CLRPF' s EV-to-FCF Range Over the Past 10 Years
Min: -31.29   Med: 0   Max: 0
Current: -31.29

CLRPF's EV-to-FCF is ranked worse than
100% of 390 companies
in the Biotechnology industry
Industry Median: 6.365 vs CLRPF: -31.29

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), Clarity Pharmaceuticals's stock price is $2.688. Clarity Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.079. Therefore, Clarity Pharmaceuticals's PE Ratio for today is At Loss.


Clarity Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Clarity Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals EV-to-FCF Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23
EV-to-FCF
- -4.57

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial - - - - -

Competitive Comparison of Clarity Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, Clarity Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clarity Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Clarity Pharmaceuticals's EV-to-FCF falls into.



Clarity Pharmaceuticals EV-to-FCF Calculation

Clarity Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=786.133/-25.542
=-30.78

Clarity Pharmaceuticals's current Enterprise Value is $786.13 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clarity Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-25.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clarity Pharmaceuticals  (OTCPK:CLRPF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Clarity Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.688/-0.079
=At Loss

Clarity Pharmaceuticals's share price for today is $2.688.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clarity Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.079.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Clarity Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Clarity Pharmaceuticals (Clarity Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.